Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Nowak

Showing results (401-410 of 441) with videos related to

Pageof 45
Sort By:
Oxford Open Immunology|January 23, 2026
Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patientsNicola Principe, Kofi L P Stevens, Amber-Lee Phung, et al.
The Lancet. Oncology|April 16, 2013
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 studyWieneke A Buikhuisen, Jacobus A Burgers, Andrew D Vincent, et al.
Frontiers in Immunology|December 2, 2020
Tumor Infiltrating Effector Memory Antigen-Specific CD8<sup>+</sup> T Cells Predict Response to Immune Checkpoint TherapyNicola Principe, Joel Kidman, Siting Goh, et al.
BMJ Open|September 14, 2022
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastomaBenjamin Y Kong, Hao-Wen Sim, Elizabeth H Barnes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
The Lancet. Oncology|September 5, 2020
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-inAnna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
Mucosal Immunology|July 6, 2021
Duplication of the IL2RA locus causes excessive IL-2 signaling and may predispose to very early onset colitisMaria E Joosse, Fabienne Charbit-Henrion, Remy Boisgard, et al.
JNCI Cancer Spectrum|May 11, 2024
Unmet needs in people with high-grade glioma: defining criteria for stepped care interventionMona M Faris, Haryana M Dhillon, Rachel Campbell, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Pageof 45

Showing results (401-410 of 441) with videos related to

Sort By:
Pageof 45
Oxford Open Immunology|January 23, 2026
Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patientsNicola Principe, Kofi L P Stevens, Amber-Lee Phung, et al.
The Lancet. Oncology|April 16, 2013
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 studyWieneke A Buikhuisen, Jacobus A Burgers, Andrew D Vincent, et al.
Frontiers in Immunology|December 2, 2020
Tumor Infiltrating Effector Memory Antigen-Specific CD8<sup>+</sup> T Cells Predict Response to Immune Checkpoint TherapyNicola Principe, Joel Kidman, Siting Goh, et al.
BMJ Open|September 14, 2022
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastomaBenjamin Y Kong, Hao-Wen Sim, Elizabeth H Barnes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
The Lancet. Oncology|September 5, 2020
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-inAnna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
Mucosal Immunology|July 6, 2021
Duplication of the IL2RA locus causes excessive IL-2 signaling and may predispose to very early onset colitisMaria E Joosse, Fabienne Charbit-Henrion, Remy Boisgard, et al.
JNCI Cancer Spectrum|May 11, 2024
Unmet needs in people with high-grade glioma: defining criteria for stepped care interventionMona M Faris, Haryana M Dhillon, Rachel Campbell, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Pageof 45